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PROCEEDINGS Open Access
Simulation of a medication and
methylation effects on triglycerides in the
Genetic Analysis Workshop 20
Aldi T. Kraja*, Ping An, Petra Lenzini, Shiou J. Lin, Christine Williams, James E. Hicks, E. Warwick Daw
and Michael A. Province*
Abstract
The GAW20 simulation data set is based upon the companion Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)
study fenofibrate clinical trial data set that forms the real data example for GAW20. The simulated data problem consists of
200 simulated replications of what might happen if we were to repeat the GOLDN clinical trial 200 independent times, for
these exact same subjects, but using a new fictitious drug (called “genomethate”) that has a pharmaco-epigenetic effect on
triglyceride response. For each replication, the pre-genomethate values at visits 1 and 2 are constant (ie, pedigree structures,
age, sex, all phenotypes, covariates, genome-wide association study (GWAS) genotypes, and visit 2 methylation values), the
same as the real GOLDN data across all 200 replications. Only the post-genomethate treatment data (ie, methylation and
triglyceride levels for visits 3 and 4) change across the 200 replications. We postulate a growth curve pharmaco-epigenetic
response model, in which each patient’s response to genomethate treatment is individualized, and is dependent upon their
genotype as well as the methylation state for key genes.
Background
The companion Genetics of Lipid Lowering Drugs and Diet
Network (GOLDN) study fenofibrate clinical trial data set
[1–3] was the foundation of our Genetic Analysis Work-
shop 20 (GAW20) simulation. The general simulation strat-
egy was to first simulate visit 4 methylation array data for
each subject (which measures the individual epigenetic
responses to genomethate treatment), and then use this
plus the genome-wide association study (GWAS) genotypes
to produce the simulated triglycerides for visits 3 and 4
post-treatment values. The main simulated effect of geno-
methate is on the phenotype of the individual subject’s tri-
glyceride (TG) values measured as slope in response to
treatment (change in mg/dL per unit time of treatment).
Methods, results and discussion
Figure 1 illustrates the graphical design of the simulations.
The j index in the figure represents the subject (j = 1, 2,
…, N = 717). The i index is noting the single-nucleotide
polymorphisms (SNPs) chosen to be causal in the simulat-
ing model (i = 1, 2, …, G = 105), where i = 1, 2, 3, 4, 5 also
indexes the 5 main effects of the corresponding nearby
cytosine-phosphate-guanine (CpG) sites, while beyond
main effects, the sites from 6 to 105 are 100 SNPs with
background genetic effects. The k index indicates replica-
tions (k = 1, 2, …, R = 200).
The first 5 causal SNPs are “major” effects (summa-
rized in Table 1), and the last 100 SNPs are polygenic
background effects (Table 2). Note that only the first 5
CpG sites are relevant to the model, the polygenic back-
ground effects do not depend upon CpG states.
We first defined a series of subjects’ triglyceride values
from the original (real) Genetics of Lipid Lowering
Drugs and Diet Network (GOLDN) data [1], which was
used to generate the simulations. Because triglycerides
were approximately log-normally distributed, we worked
with log-transformed triglyceride values in all calculations,
only transforming back to the measured triglyceride scale
at the end of the simulations. In particular, for the jth
subject, the average log triglycerides pre-treatment (aver-
age of visits 1 and 2, which are 1 day apart) and* Correspondence: aldikraja@wustl.edu; mprovince@wustl.eduDivision of Statistical Genomics, Department of Genetics and Center for
Genome Sciences and Systems Biology, Washington University School of
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post-treatment (average of visits 3 and 4, which are also
1 day apart) in the original (real) GOLDN data are:
O preRx TG j¼mean log TG1 j
 
; log TG2 j
  
O postRx TG j¼mean log TG3 j
 
; log TG4 j
  
where O –stands for “Observed / Original”, preRx
stands for “pre-medication treatment,” postRx stands for
“after medication treatment,” and TG labels “triglycer-
ides” which were log transformed to ensure a normal
distribution of the trait. The TG of person j is measured
in visits 1, 2, 3 and 4 and averaged as above for each in-
dividual as preRx and postRx. The corresponding
change in log triglycerides pre-treatment to post-
treatment for subject j is given by:
O delta TG j¼ O postRx TG j−O preRx TG j
 
where delta is the “change”. The individual time on
treatment (less than 30 days) for each subject (in days),
is given by the following formula:
O daysRxj¼mean draw date v3 j;draw date v4 j
 
−draw date v2 j
where daysRx is “days after medication treatment,”
draw_date is “blood draw date” at a particular v- “visit.”
Thus, the observed slope (change in log triglycerides
over the treatment period) is:
O slope TG j¼O delta TG j=O daysRxj
If mean_O_PreRx_TG and sd_O_preRx_TG are the
mean and standard deviations, respectively, of all the
O_preRx_TGj across the j = 1, …, N individuals, then
the standardized original preRx of TGj are given by:
O preZ j¼ O preRx TG j−mean O PreRx TG
 
=sd O preRx TG
where O_preZ -is a standardized normally distributed
variable with N(0,1).
Fig. 1 A 3D indexing order of the GAW20 simulation. The j index in the figure represents the subjects, the i index is noting the causal SNPs,
where i = 1–5 also indexes the 5 main effects of the corresponding nearby CpG sites, while the sites 6–105 are 100 SNPs with background
genetic effects. The k index indicates replications (k = 1, 2, …, R = 200)
Table 1 Five major effect causal SNPs and corresponding nearby CpG markers affecting triglycerides at visits 3 and 4
Methylvar chrom cgposition cggene CpG CpG Cp CpG markname chrom rsposition rsgene role hg2 diffpos
mean Sd Gmean Sd
V2 V2 V4 V4
cg00000363 1 230560793 0.488 0.0589 0.492 0.3273 rs9661059 1 230556033 0.125 − 4760
cg10480950 6 5067127 0.578 0.0571 0.56 0.3247 rs736004 6 5067728 LYRM4 intron 0.075 601
cg18772399 8 89478349 0.575 0.0743 0.556 0.3265 rs1012116 8 89466383 0.100 −11966
cg00045910 10 23466070 0.474 0.0896 0.482 0.3295 rs10828412 10 23476515 0.025 10445
cg01242676 17 13413600 HS3ST3A1 0.456 0.0837 0.464 0.328 rs4399565 17 13407619 HS3ST3A1 intron 0.050 − 5981
Abbreviations: methylvar, CpG marker name; chrom, CpG marker’s chromosome; cgposition, CpG marker position in base pairs; cggene, CpG marker’s gene; CpGmeanV2,
mean of methylation at visit 2; CpGSdV2, standard deviation of the same methylation marker at visit 2; CpGmeanV4, mean of methylation at visit 4; CpGSdV4, standard
deviation of the same methylation marker at visit 4; markname, SNP name; chrom, SNP’s chromosome; rsposition, SNP’s position in base pairs; rsgene, SNP’s gene name;
role, SNP’s role; hg2, simulated expected heritability for each causative SNP; diffpos, difference in base pair positions between corresponding SNP and CpG markers






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Kraja et al. BMC Proceedings 2018, 12(Suppl 9):25 Page 15 of 258
Tables 1 and 2 summarize the epigenetic model in our
simulation. We chose 5 “major gene” causal variants
(ranging from modest to small effect sizes corresponding
to expected “heritabilities” of 0.125, 0.10, 0.075, 0.05,
and 0.025), which, in the absence of any epigenetic ef-
fects, should govern individual genomethate treatment
response along with 100 polygene variants (each of tiny
effect size corresponding to “heritabilities” of 0.001
each). These were chosen randomly from chromosomes
1–20 of the GWAS Affymetrix Genome-wide Human
SNP Array 6.0, which had 718,544 autosomal SNPs.
For the epigenetic component, we choose 5 CpG sites
on the Illumina Infinium HumanMethylation450 Bead-
Chip array (which had 463,995 CpG sites) that are phys-
ically closest to the 5 “major gene” causal SNPs, while
the methylation sites near the 100 polygenes have no ef-
fect. The genomethate response model is based upon
the idea that these CpG sites need to be sufficiently
unmethylated for the corresponding causal SNPs to ex-
press their influence on each individual’s phenotype. If
the nearby CpG site is totally methylated (=1), then the
corresponding causal SNP actually has no effect on the
phenotype. If the CpG site is totally unmethylated (=0),
then the corresponding causal SNP carries its full effect
size impact on the phenotype. If the CpG site is partially
methylated (between 0 and 1), then the effect size of the
causal SNP is proportionally attenuated.
Specifically, for the kth simulation, we first generated
the simulated visit 4 methylation array results for all
subjects, based upon their corresponding visit 2 and/ or
visit 4 methylation values. For each subject j = 1, …, 717,
and each CpG methylation site i = 1, 2, 3, 4, 5 (corre-
sponding to 5 major effect CpGs)
sim meth v4jik¼real meth v2jiþsdiZ1jik
where sim_meth stands for “simulated methylation” at
visit 4, real_meth is the jth subject’s “real methylation”
array data at visit 2 for the ith CpG site, sdi = 0.4 repre-
sents the standard deviation of individual subject methy-
lation responses to treatment, and Z1jik ~ N(0, 1) is a
pseudo-random standard normal variable drawn inde-
pendently for each jik.
For the remaining, non-causal CpG sites, if the subject
j had real visit 4 methylation array data then
sim meth v4jik¼real meth v4jiþsdiZ1jik
Otherwise, if the subject j only had visit 2 methylation
array data, then
sim meth v4jik¼real meth v2jiþsdiZ1jik
where real_meth_v2ji and real_meth_v4ji are the real
visit 2 and visit 4 methylation array data, respectively,
for subject j and CpG site i, sdi represents the standard
deviation of individual subject methylation responses to
treatment for the ith CpG site, and again, Z1jik ~ N(0,1)
is a pseudo-random variable drawn independently for
each jik.
We selected five random non-causal (red-herrings)
CpG sites also (shown in Table 3). We set for them the
sdi = 0.4, to be similar to the simulated causal CpG sites.
For the remaining non-causal CpG sites, we set the cor-
responding sdi = 0.03, which is closer to that seen in the
real visit 4 methylation data CpG sites, essentially at the
measurement error level.
In all cases, all simulated visit 4 methylation values
were then truncated to be strictly in the [0,1] interval,
that is,
if (sim_meth_v4jik > 1) then sim_meth_v4jik = 1
if (sim_meth_v4jik < 0) then sim_meth_v4jik = 0
for all subjects j, CpG sites i, and simulation repli-
cations k.
Note that the model is such that, on average, the geno-
methate treatment has no effect on the amount of
methylation increase/decrease from visit 2 to visit 4,
however, there is variability across subjects. To reiterate,
the variability is quite high (sdi = 0.4) for the five CpG
regions controlling the expression of the major causal
variants and 5 other non-causal CpG (red-herrings) sites.
The variability is low (sdi = 0.03) for all other CpGs, at
the level of measurement error.
Using these simulated visit 4 methylation data, we
then generated the simulated slope change in triglycer-




i¼1 1−sim meth v4jik
   sqrt hg2ið Þ
SSNPji þ
X105
i¼6sqrt hg2ið Þ  SSNPji






In the above formula, zenvjk is an independently drawn
pseudo-random normal deviate distributed N(0,1) for each
subject j and each replication k, and it represents
unexplained residual variation in the phenotype. SSNPji is
the standardized ith SNP additive genotype-dosage (i.e.,
coded such that mean = 0 and sdi = 1 in the sample), and
the i = 1, 2, …, 105 regression coefficients in this linear
model are given in terms of constants sqrt(hg2i), in
Tables 1 and 3. Note that if the five causal CpG sites
were completely unmethylated for all subjects (i.e., no
epigenetic effects), then (1 – sim_meth_v4 jik) would be = 1
for all j = 1,…, N and i = 1,…, 5, and k = 1,…, 200, so that
the regression coefficients would be interpreted as the
square root of the locus specific heritability of the
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associated SNPs. Conversely, when the causal CpG site is to-
tally methylated for that subject, (1 - sim_meth_v4 jik) = 0,
so that the corresponding major effect SNPi will not
express its effect on the phenotype. Similarly, if the
CpG site is partially methylated (between 0 and 1),
the effect size of the causal SNP is proportionally
attenuated.
To carry forward these simulated relationships in
eq. (1), we must address the fact that the observed
slope responses for each subject are correlated to
their baseline values of triglyceride (i.e., lower base-
line values should produce less dramatic declines
with treatment, whereas higher baseline values can
experience greater slope change with treatment). In
the real GOLDN data, the correlation between slope
change in response to fenofibrate treatment and
baseline log triglycerides is − 0.41881, and we used
this constant value in our genomethate simulation to
introduce a correlation between slope change and
baseline values:
corrzjk¼ −0:41881ð ÞO preZ jþsqrt 1− 0:41881ð Þ2
 
slopejk
Because the simulated individual slopes are gener-
ated on the standardized scale, we needed to rescale
to that of the original scale of triglyceride changes
per day of treatment, by working backwards. The
mean and standard deviation of O_slope_TGj over
all subjects j, are denoted by mean_O_slope_TG
and sd_O_slope_TG, respectively. We used the
above observed mean and standard deviation of
slopes seen in the original GOLDN data, to rescale
as follows:
sim slopejk¼corrzjksd O slope TG
þmean O slope TG
Then the expected response to genomethate treatment
of the jth subject, after O_DaysRxj original days of treat-
ment, is given by:
sim postRx TGjk¼ sim slopejkO DaysRxj
 
þO preRx TG j
Finally, we used the simulated individual responses
to produce the simulated values of triglyceride at
visits 3 and 4, based upon the variability we see be-
tween those visits in the real GOLDN fenofibrate
data:
sim TG3jk ¼ exp½sim postRx TGjk
þ logðTG3 j
 
−O postRx TG jÞ
ð2Þ
sim TG4jk ¼ exp½sim postRx TGjk
þ logðTG4 j
 
−O postRx TG jÞ
ð3Þ
If only 1 replicate of the GAW20 simulated data was to
be analyzed, we recommend the 84th replication, which
was provided in a separate directory, as a “representative”
of the 200 replicated simulations. Chromosomes 21 and
22 datasets were not used in the simulation, so an analyst
can use the corresponding data for building a NULL
hypothesis. The simulated GAW20 data are accompanied
by README and Data Dictionary files.
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